ArticleScientific reports2026
Association of statin therapy on acute ischemic stroke patients with atrial fibrillation: insights from a nationwide cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Although statins are well-established in improving outcomes after ischemic stroke, their effectiveness in patients with acute ischemic stroke (AIS) and atrial fibrillation (AF) without conventional indications remains uncertain. This study investigates the association between statin therapy and vascular outcomes in patients with AIS and AF without previously diagnosed atherosclerotic cardiovascular disease (ASCVD). This retrospective, nationwide cohort study utilized the Korean National Health Insurance Service database (2011–2023). Patients aged ≥ 20 years with AIS or transient ischemic attack and concurrent AF were included if they underwent neuroimaging, had no prior statin use at admission, and no documented history of ASCVD. Propensity score matching and inverse probability of treatment weighting (IPTW) were used to adjust for potential confounders. The primary outcome was a composite of all-cause death, ischemic stroke or systemic embolism, intracranial hemorrhage (ICH), and myocardial infarction within 1 year. Hazard ratios (HR) were estimated using Cox regression. Subgroup analyses assessed the association of statin dose (high vs. standard), ezetimibe combination therapy, and statin type. A total of 64,190 patients (mean age; 73.76, male 55.3%) were finally analyzed and categorized into statin users (n = 37,033) and non-users (n = 27,157). In the IPTW analysis, statin-user was associated with lower risk for primary vascular outcomes (HR 0.821 [95% CI 0.808–0.835]), mortality (HR 0.746 [0.729–0.763]), ischemic stroke and systemic embolism (HR 0.904 [0.884–0.925]), and ICH (HR 0.725 [0.660–0.796]) compared to non-users. Neither statin dose, statin type, nor ezetimibe combination was significantly associated with differences in the primary outcome. In patients with AIS and AF without previously diagnosed ASCVD, statin therapy was associated with a lower risk of major vascular events. These findings suggest a potential benefit of statins in this population and highlight the need for confirmation through prospective randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.